Previous 10 | Next 10 |
Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...
Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure thr...
Whenever your stock tumbles due to a temporary issue, it will nearly always rebound at resolution in the ensuing months. Iovance Biotherapeutics' potency assay for lifileucel caused a huge haircut in the share price. As Iovance has now resolved the assay debacle, the stock is pois...
ZUG, Switzerland and CAMBRIDGE, Mass., April 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board...
Iovance Biotherapeutics (NASDAQ:IOVA) is trading higher after Baird raised its per share by more than 10%, noting the recent feedback the clinical-stage biotech received from the U.S. Food and Drug Administration (FDA) on lifileucel, an experimental therapy for metastatic melanoma. Annou...
Iovance Biotherapeutics (NASDAQ:IOVA) said it had received a positive feedback from the U.S. Food and Drug Administration (FDA) regarding its potency matrix assays, which will support a Biologics License Application for lifileucel in metastatic melanoma. The company said it will request ...
Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileucel in Combination with Pembrolizumab SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-...
Iovance Biotherapeutics focuses on developing treatments for cancers, a market with minimal supply and large demand. The company recently received approval to proceed with further investigations into a revolutionary new treatment for NSCLCs. The company relies on smart partnership...
The shares of Iovance Biotherapeutics (IOVA +7.1%) surged after CNBC market commentator Jon Najarian issued positive remarks on the clinical-stage biotech company on Wednesday. Citing April 25 call volume of Iovance (NASDAQ:IOVA), Najarian noted with interest that the company presents at mult...
Gainers: OraSure Technologies (NASDAQ:OSUR) +5%, Iovance Biotherapeutics (NASDAQ:IOVA) +4%, Marqeta (NASDAQ:MQ) +3%, Chimerix (NASDAQ:CMRX) +3%, Ribbon Communications (NASDAQ:RBBN) +3%. Losers: Incannex Healthcare (NASDAQ:IXHL) -10%, CarParts.com (NASDAQ:PRTS) -5%, Eargo (NASDAQ:EAR) -5%...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...